The Association Study of Plasma Levels of Pigment Epithelium-Derived Factor with Acute Coronary Syndrome in the Chinese Han Population

Abstract

Objects: To investigate the relationship between plasma levels of pigment epithelium-derived factor (PEDF) and acute coronary syndrome (ACS) in the Chinese Han population. Methods: Plasma PEDF levels were measured in 200 consecutive ACS patients and 160 age- and sex-matched healthy control subjects. Logistic regression analysis was performed to determine whether PEDF was an independently protective factor against ACS. All ACS patients were followed up for 6 months and the short-term major adverse cardiovascular events (MACE) were obtained: cardiac death and recurrent angina. Results: The ACS patients showed notably lower plasma PEDF levels relative to the control group (7.31 ± 2.21 vs. 8.44 ± 2.13 μg/ml, respectively, p = 0.001). Logistic regression analysis revealed that PEDF had a significant protective effect against ACS (OR = 0.76, 95% CI 0.623-0.935, p = 0.01). After 6 months of follow-up, we found that the mean PEDF concentration of the patients with short-term MACE was lower than the patients without (6.05 ± 2.18 vs. 7.52 ± 2.07 µg/ml, p = 0.031). The Kaplan-Meier survival curves suggested that patients with plasma PEDF levels <7.00 µg/ml showed a lower survival trend than those in the higher group, but the difference was not significant (p = 0.477). Conclusions: Our study indicates that plasma PEDF levels are significantly lower in ACS patients than in controls, and lower PEDF levels are further associated with adverse cardiac outcomes after ACS.

Novel Biomarker MicroRNAs for Subtyping of Acute Coronary Syndrome: A Bioinformatics Approach

“…PEDF, a 50-kDa glycoprotein, has anti-inflammatory, antioxidant, antiangiogenic, antithrombotic, antitumorigenic, and neuroprotective properties [82] and is widely expressed throughout the human body. In ACS patients, plasma PEDF concentrations were significantly lower than the control group and associated with adverse cardiac outcomes after ACS [83]. PEDF can block platelet activation and aggregation [84] through its anti-inflammatory and antioxidative properties, leading to the inhibition of the vascular inflammation and the formation of a thrombus [85].…”

The effects of pigment epithelium-derived factor on atherosclerosis: putative mechanisms of the process

“…ACS patients, however, had decreased plasma and intraplatelet level of PEDF [ 16 ]. Meanwhile, we have previously shown that ACS patients had notably lower plasma PEDF level relative to the control group and lower PEDF level was further related to adverse cardiac outcomes after ACS [ 19 ], and that PEDF level remarkably decreased in CAD patients compared to the controls [ 20 ]. Therefore, it is not yet clear whether high or low PEDF serum level accelerates the development of these diseases.…”

“…Additionally, our group has carried out recent studies on PEDF, ranging from clinical issues to molecular mechanisms. Initially, we found that plasma PEDF level was significantly lower in ACS patients, and lower PEDF level was associated with adverse cardiac outcomes after ACS [ 19 ]. Furthermore, our data showed that plasma PEDF level was significantly lower in CAD patients and PEDF may be used as a potential predicator for coronary severity [ 20 ].…”

Association of Pigment Epithelium Derived Factor With von Willebrand Factor and Plasminogen Activator Inhibitor 1 in Patients With Type 2 Diabetes

“…However, due to cross-sectional design of these studies there are questions of whether elevation of PEDF was a cause or consequence of impaired vascular function, inflammation and atherosclerosis and whether PEDF levels are not elevated as a compensatory countersystem to attenuate the inflammation and atherosclerosis. Liu et al (2014) reported that plasma levels of PEDF were decreased in patients with acute coronary syndrome relative to control subjects, and lower PEDF values could predict future adverse CV events in these patients.…”